

Alfonso Iorio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3991016/alfonso-iorio-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

12,344
citations

51
h-index

101
g-index

414
ext. papers

15,023
ext. citations

6
avg, IF

6.26
L-index

#	Paper	IF	Citations
382	User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study.. <i>JMIR Human Factors</i> , 2022 , 9, e30797	2.5	1
381	Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature.. <i>Journal of Medical Internet Research</i> , 2022 , 24, e30791	7.6	5
380	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia.. <i>HemaSphere</i> , 2022 , 6, e694	0.3	
379	Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12661	5.1	0
378	Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.. <i>Vaccine</i> , 2022 ,	4.1	0
377	Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance.. <i>BMJ Evidence-Based Medicine</i> , 2022 ,	2.7	1
376	Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal.. <i>BMJ Evidence-Based Medicine</i> , 2022 ,	2.7	1
375	Emicizumab state-of-the-art update.. <i>Haemophilia</i> , 2022 , 28 Suppl 4, 103-110	3.3	0
374	External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12599	5.1	
373	Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method. <i>BMC Geriatrics</i> , 2021 , 21, 665	4.1	1
372	GRADE concept paper 2: Concepts for Judging Certainty on the Calibration of Prognostic Models in a Body of Validation Studies. <i>Journal of Clinical Epidemiology</i> , 2021 ,	5.7	4
371	Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. <i>Blood</i> , 2021 , 138, 4990-4990	2.2	
370	Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. <i>Blood</i> , 2021 , 138, 347-347	2.2	
369	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. <i>Haemophilia</i> , 2021 , 27, e525-e529	3.3	1
368	The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12601	5.1	1
367	Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 251-260	6.4	0
366	Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. <i>Haemophilia</i> , 2021 , 27, 358-365	3.3	3

365	Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12488	5.1	7
364	A Deep Learning Approach to Refine the Identification of High-Quality Clinical Research Articles From the Biomedical Literature: Protocol for Algorithm Development and Validation. <i>JMIR Research Protocols</i> , 2021 , 10, e29398	2	2
363	Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. <i>Haemophilia</i> , 2021 , 27, 626-633	3.3	0
362	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. <i>Journal of Trauma and Acute Care Surgery</i> , 2021 , 91, S19-S25	3.3	6
361	Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. <i>Haemophilia</i> , 2021 , 27, e596-e608 ¹	3.3	6
360	Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes. <i>Haemophilia</i> , 2021 , 27, 751-759	3.3	1
359	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1896-1906	15.4	4
358	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 33-42	35.1	31
357	GRADE Concept Paper 1: Validating the "F.A.C.E" instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implement. <i>Journal of Clinical Epidemiology</i> , 2021 , 131, 133-140	5.7	1
356	Interventions to Influence Opioid Prescribing Practices for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. <i>American Journal of Preventive Medicine</i> , 2021 , 60, e15-e26	6.1	4
355	Non-severe haemophilia: Is it benign? - Insights from the PROBE study. <i>Haemophilia</i> , 2021 , 27 Suppl 1, 17-24	3.3	6
354	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. <i>Haemophilia</i> , 2021 , 27, 211-220	3.3	2
353	Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, 349-355 ¹	5.1	1
352	Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. <i>The Cochrane Library</i> , 2021 , 8, CD014201	5.2	1
351	A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. <i>Journal of Clinical Epidemiology</i> , 2021 ,	5.7	2
350	Evaluation of the sexual health in people living with hemophilia. <i>Haemophilia</i> , 2021 , 27, 993-1001	3.3	1
349	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021 , 5, 4721-4726	7.8	3
348	Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review. <i>JMIR Medical Informatics</i> , 2021 , 9, e30401	3.6	4

347	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , 2021 , 138, 115-127	5.7	1
346	Optimizing a literature surveillance strategy to retrieve sound overall prognosis and risk assessment model papers. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021 , 28, 766-771	8.6	0
345	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. <i>BMC Medical Research Methodology</i> , 2020 , 20, 113	4.7	12
344	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. <i>Blood</i> , 2020 , 135, 1788-1810	2.2	33
343	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , 2020 , 4, 2351-2365	7.8	16
342	The World Federation of Hemophilia Annual Global Survey 1999-2018. <i>Haemophilia</i> , 2020 , 26, 591-600	3.3	18
341	Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. <i>Blood Advances</i> , 2020 , 4, 2557-2566	7.8	7
340	Psychological interventions for people with hemophilia. <i>The Cochrane Library</i> , 2020 , 3, CD010215	5.2	3
339	Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 326-333	5.1	7
338	Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates. <i>Haemophilia</i> , 2020 , 26, 282-289	3.3	4
337	GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. <i>Journal of Clinical Epidemiology</i> , 2020 , 121, 62-70	5.7	86
336	Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dioxygenase-1 and Heme Oxygenase-1. <i>Frontiers in Immunology</i> , 2020 , 11, 620	8.4	1
335	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1940-1951	15.4	24
334	Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. <i>Haemophilia</i> , 2020 , 26, 384-400	3.3	14
333	COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. <i>Journal of Clinical Epidemiology</i> , 2020 , 123, 120-126	5.7	93
332	Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments. <i>Blood</i> , 2020 , 136, 22-23	2.2	
331	Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database. <i>Blood</i> , 2020 , 136, 21-22.2		
330	Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIc) in Patients with Severe Hemophilia A. <i>Blood</i> , 2020 , 136, 24-25	2.2	

329	Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. <i>Blood</i> , 2020 , 136, 37-38	2.2	
328	Predictors of treatment adherence in patients with chronic disease using the Multidimensional Adherence Model: unique considerations for patients with haemophilia. <i>The Journal of Haemophilia Practice</i> , 2020 , 7, 92-101	0.2	2
327	Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study. <i>JMIR Medical Education</i> , 2020 , 6, e16777	5	1
326	Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. <i>BMJ Open</i> , 2020 , 10, e040122	3	0
325	Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis. <i>Health Psychology</i> , 2020 , 39, 430-451	5	5
324	Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. <i>Haemophilia</i> , 2020 , 26, 56-63	3.3	5
323	Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 605-616	6.2	6
322	Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. <i>Blood Advances</i> , 2020 , 4, 4929-4944	7.8	8
321	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2496-2502	15.4	57
320	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2486-2495	15.4	36
319	A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. <i>Thrombosis Research</i> , 2020 , 196, 550-558	8.2	1
318	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2503-2512	15.4	9
317	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3074-3077	15.4	11
316	Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. <i>Annals of Hematology</i> , 2020 , 99, 2689-2698	3	11
315	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020 , 7, e746-e755	14.6	8
314	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. <i>Haemophilia</i> , 2020 , 26, 966-974	3.3	3
313	Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest. <i>Journal of Clinical Epidemiology</i> , 2020 , 117, 46-51	5.7	9
312	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 245-256	6.2	13

311	Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 368-376 ⁷		15
310	Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. <i>Annals of Hematology</i> , 2019 , 98, 2035-2044 ³		18
309	Defining certainty of net benefit: a GRADE concept paper. <i>BMJ Open</i> , 2019 , 9, e027445	3	19
308	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 528-541	5.1	11
307	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019 , 46, 427-438	2.7	7
306	Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019 , 46, 411-426	2.7	18
305	Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1085-1096	15.4	27
304	Hemophilia trials in the twenty-first century: Defining patient important outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 184-192	5.1	22
303	Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. <i>Haemophilia</i> , 2019 , 25, 365-372	3.3	9
302	Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 12-14	5.1	4
301	An evidence rating service provided valid correlates of the clinical importance of medical articles and journals. <i>Journal of Clinical Epidemiology</i> , 2019 , 109, 80-89	5.7	
300	Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. <i>BMC Medical Research Methodology</i> , 2019 , 19, 67	4.7	17
299	The association between platelet transfusions and mortality in patients with critical illness. <i>Transfusion</i> , 2019 , 59, 1962-1970	2.9	4
298	Emicizumab and thrombosis: The story so far. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 1269-1272 ^{15.4}		31
297	Joint Bleeding Tendencies in Adult Patients With Hemophilia: It's Not All Pharmacokinetics. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619862052	3.3	6
296	Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins. <i>Microporous and Mesoporous Materials</i> , 2019 , 287, 220-227	5.3	6
295	A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. <i>Thrombosis Research</i> , 2019 , 184, 31-37	8.2	1
294	Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. <i>South African Medical Journal</i> , 2019 , 109, 639-644	1.5	1

293	Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A. <i>Blood</i> , 2019 , 134, 3637-3637 ^{2,2}	2.2	1
292	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. <i>Blood Transfusion</i> , 2019 , 17, 391-398 ^{3,6}	3.6	13
291	Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products. <i>Blood</i> , 2019 , 134, 2405-2405	2.2	
290	Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. <i>Blood</i> , 2019 , 134, 1178-1178	2.2	
289	Switching patients in the age of long-acting recombinant products?. <i>Expert Review of Hematology</i> , 2019 , 12, 1-13	2.8	8
288	Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. <i>Annals of Internal Medicine</i> , 2019 , 171, 540-546	8	115
287	Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. <i>Haemophilia</i> , 2019 , 25, 75-83	3.3	10
286	Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. <i>Journal of Clinical Epidemiology</i> , 2018 , 99, 14-23	5.7	18
285	Point-of-care ultrasonography in haemophilia care: Training and competency for muscular haematomas. <i>Haemophilia</i> , 2018 , 24, 335-337	3.3	4
284	World bleeding disorders registry: The pilot study. <i>Haemophilia</i> , 2018 , 24, e113-e116	3.3	10
283	Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. <i>Haemophilia</i> , 2018 , 24, e6-e10	3.3	7
282	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018 , 131, 430-437	2.4	11
281	Guideline on terminology and definitions of updating clinical guidelines: The Updating Glossary. <i>Journal of Clinical Epidemiology</i> , 2018 , 95, 28-33	5.7	4
280	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. <i>Pilot and Feasibility Studies</i> , 2018 , 4, 58	1.9	21
279	Haemophilia clinical care and research needs: Assessing priorities. <i>Haemophilia</i> , 2018 , 24, e270-e273	3.3	
278	The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. <i>Thrombosis Research</i> , 2018 , 170, 53-59	8.2	3
277	Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research.. <i>Canadian Journal of Pain</i> , 2018 , 2, 191-204	1.5	13
276	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. <i>BMJ Open</i> , 2018 , 8, e021900	3	12

275	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. <i>Haemophilia</i> , 2018 , 24, 726-732	3.3	5
274	Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. <i>Haemophilia</i> , 2018 , 24 Suppl 6, 60-67	3.3	28
273	A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10281	7.6	21
272	Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform. <i>Blood</i> , 2018 , 132, 1191-1191	2.2	
271	Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. <i>Blood</i> , 2018 , 132, 4813-4813	2.2	1
270	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. <i>Blood</i> , 2018 , 132, 3781-3781	2.2	
269	Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review. <i>Systematic Reviews</i> , 2018 , 7, 189	3	5
268	Focusing in on use of pharmacokinetic profiles in routine hemophilia care. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 607-614	5.1	8
267	Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 1437-1441	15.4	29
266	Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. <i>Haemophilia</i> , 2018 , 24, e167-e172	3.3	50
265	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 535-548	5.1	30
264	McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 1656	15.4	53
263	A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2017 , 84, 37-46	5.7	32
262	Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. <i>Haemophilia</i> , 2017 , 23, 255-263	3.3	7
261	Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development. <i>Haemophilia</i> , 2017 , 23, 350-352	3.3	13
260	Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products. <i>Haemophilia</i> , 2017 , 23, 408-416	3.3	18
259	Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. <i>British Journal of Haematology</i> , 2017 , 178, 20-31	4.5	8
258	What is the role for population pharmacokinetics in hemophilia?. <i>International Journal of Pharmacokinetics</i> , 2017 , 2, 125-136	0.3	6

257	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. <i>Current Heart Failure Reports</i> , 2017 , 14, 197-202	2.8	11
256	Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1322-1333	15.4	36
255	Oral contraceptive use is a provoking factor for venous thromboembolism. <i>BMJ, The</i> , 2017 , 357, j2073	5.9	2
254	Guideline for opioid therapy and chronic noncancer pain. <i>Cmaj</i> , 2017 , 189, E659-E666	3.5	350
253	GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. <i>Journal of Clinical Epidemiology</i> , 2017 , 87, 14-22	5.7	85
252	The GRADE Working Group clarifies the construct of certainty of evidence. <i>Journal of Clinical Epidemiology</i> , 2017 , 87, 4-13	5.7	227
251	Computer-Aided Systematic Review Screening Comes of Age. <i>Annals of Internal Medicine</i> , 2017 , 167, 210-211	8	3
250	Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics - impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment. <i>Haemophilia</i> , 2017 , 23, 488-490	3.3	1
249	Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. <i>Haemophilia</i> , 2017 , 23, e170-e179	3.3	45
248	The current state of adverse event reporting in hemophilia. <i>Expert Review of Hematology</i> , 2017 , 10, 161-168	1.68	1
247	Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. <i>Journal of Medical Economics</i> , 2017 , 20, 337-344	2.4	9
246	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. <i>Annals of Internal Medicine</i> , 2017 , 166, 279-290	8	115
245	Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. <i>Haemophilia</i> , 2017 , 23, e1-e7	3.3	9
244	Discrimination and Calibration of Clinical Prediction Models: UsersPGuides to the Medical Literature. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1377-1384	27.4	456
243	Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. <i>PLoS ONE</i> , 2017 , 12, e0171028	3.7	18
242	McMaster Optimal Aging Portal: an evidence-based database for geriatrics-focused health professionals. <i>BMC Research Notes</i> , 2017 , 10, 271	2.3	9
241	Using pharmacokinetics to individualize hemophilia therapy. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 595-604	3.1	29
240	If You Build It, Who Will Come? A Description of User Characteristics and Experiences With the McMaster Optimal Aging Portal. <i>Gerontology and Geriatric Medicine</i> , 2017 , 3, 2333721417737681	2.3	6

239	Overall prognosis of preschool autism spectrum disorder diagnoses. <i>The Cochrane Library</i> , 2017 ,	5.2	3
238	Thrombosis in Inherited Fibrinogen Disorders. <i>Transfusion Medicine and Hemotherapy</i> , 2017 , 44, 70-76	4.2	39
237	Switching to extended half-life products in Canada - preliminary data. <i>Haemophilia</i> , 2017 , 23, e365-e367	3.3	24
236	Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation. <i>Haemophilia</i> , 2017 , 23, 648-651	3.3	10
235	Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1878-1881	15.4	9
234	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017 , 160, 97-104	8.2	11
233	Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 2461-2465	15.4	50
232	Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals. <i>Diagnostic and Prognostic Research</i> , 2017 , 1, 9	5.5	4
231	A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument. <i>International Urology and Nephrology</i> , 2017 , 49, 273-284	2.3	22
230	The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study. <i>Haemophilia</i> , 2017 , 23, 89-97	3.3	12
229	Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts. <i>Journal of Clinical Epidemiology</i> , 2017 , 81, 3-12	5.7	21
228	Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 589-594	7	11
227	Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1023-1030	7	30
226	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. <i>Pharmaceutics</i> , 2017 , 9,	6.4	14
225	The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1313-1321	5.5	37
224	Care models in the management of haemophilia: a systematic review. <i>Haemophilia</i> , 2016 , 22 Suppl 3, 31-40	3.3	14
223	Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1668-72	15.4	6
222	Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases. <i>Haemophilia</i> , 2016 , 22 Suppl 3, 41-50	3.3	12

221	Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. <i>Haemophilia</i> , 2016 , 22, 912-918	3.3	45
220	Interpreting trial sequential analysis. <i>Transfusion</i> , 2016 , 56, 2918-2922	2.9	4
219	Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study. <i>Haemophilia</i> , 2016 , 22 Suppl 3, 23-30	3.3	6
218	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 879-890	7	95
217	Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. <i>BMJ Open</i> , 2016 , 6, e010983	3	80
216	Variation of DNA Fragmentation Levels During Density Gradient Sperm Selection for Assisted Reproduction Techniques: A Possible New Male Predictive Parameter of Pregnancy?. <i>Medicine (United States)</i> , 2016 , 95, e3624	1.8	49
215	A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. <i>BMC Hematology</i> , 2016 , 16, 17	2.5	3
214	Systematic reviews experience major limitations in reporting absolute effects. <i>Journal of Clinical Epidemiology</i> , 2016 , 72, 16-26	5.7	31
213	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016 , 203, 785-90	3.2	1
212	The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels. <i>Implementation Science</i> , 2016 , 11, 93	8.4	31
211	Clinical and Biological Determinants of Bleeding Manifestation in Congenital Factor XI Deficiency; A Systematic Review. <i>Blood</i> , 2016 , 128, 1407-1407	2.2	1
210	Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis. <i>Blood</i> , 2016 , 128, 1408-1408	2.2	1
209	Perioperative Management for Congenital Factor XI Deficiency; A Systematic Review. <i>Blood</i> , 2016 , 128, 3796-3796	2.2	2
208	The Effect of Platelet Transfusion on Death in the Intensive Care Unit. <i>Blood</i> , 2016 , 128, 3850-3850	2.2	1
207	Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0156891	3.7	52
206	The McMaster Optimal Aging Portal: Usability Evaluation of a Unique Evidence-Based Health Information Website. <i>JMIR Human Factors</i> , 2016 , 3, e14	2.5	17
205	User Experiences of the McMaster Optimal Aging Portal's Evidence Summaries and Blog Posts: Usability Study. <i>JMIR Human Factors</i> , 2016 , 3, e22	2.5	5
204	Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. <i>JMIR Research Protocols</i> , 2016 , 5, e239	2	71

203	Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). <i>JMIR Research Protocols</i> , 2016 , 5, e232	2	34
202	Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives. <i>Blood</i> , 2016 , 128, 2563-2563	2.2	
201	Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (Wilate [®]). <i>Blood</i> , 2016 , 128, 2593-2593	2.2	
200	Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2016 , 128, 3821-3821	2.2	
199	Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. <i>Journal of Blood Medicine</i> , 2016 , 7, 239-253	2.3	4
198	FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. <i>Haemophilia</i> , 2016 , 22, e36-8	3.3	10
197	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016 , 6, e010569	3	14
196	Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management. <i>Haemophilia</i> , 2016 , 22 Suppl 3, 17-22	3.3	10
195	NHF-McMaster Guideline on Care Models for Haemophilia Management. <i>Haemophilia</i> , 2016 , 22 Suppl 3, 6-16	3.3	40
194	Individual participant data meta-analyses compared with meta-analyses based on aggregate data. <i>The Cochrane Library</i> , 2016 , 9, MR000007	5.2	41
193	Report on the International Society for Laboratory Hematology Survey on guidelines to support clinical hematology laboratory practice. <i>International Journal of Laboratory Hematology</i> , 2016 , 38 Suppl 1, 133-8	2.5	2
192	Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 775-81	15.4	45
191	How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 1325-35	5.7	50
190	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , 2015 , 26, 330-7	3.9	18
189	Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. <i>BMC Hematology</i> , 2015 , 15, 4	2.5	18
188	Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors. <i>Haemophilia</i> , 2015 , 21, 116-23	3.3	9
187	Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. <i>Haemophilia</i> , 2015 , 21, e26-38	3.3	24
186	Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. <i>Haemophilia</i> , 2015 , 21, e156-66	3.3	13

185	Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. <i>BMJ Open</i> , 2015 , 5, e009368	3	17
184	Individualizing factor replacement therapy in severe hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 864-71	5.3	14
183	Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. <i>Blood</i> , 2015 , 125, 3816-7	2.2	9
182	Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 958-67	7	43
181	Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2015 , 10, 28915	2	14
180	Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. <i>Haemophilia</i> , 2015 , 21, 828-31	3.3	9
179	Inhibitor development in non-severe haemophilia across Europe. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 670-5	7	11
178	Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. <i>The Cochrane Library</i> , 2015 , CD004449	5.2	4
177	A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. <i>Haemophilia</i> , 2015 , 21, 731-5	3.3	19
176	Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study). <i>Haemophilia</i> , 2015 , 21, 736-41	3.3	21
175	Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 56-64	7	3
174	Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 968-75	7	89
173	Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. <i>BMJ, The</i> , 2015 , 350, h870	5.9	304
172	Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. <i>Haemophilia</i> , 2015 , 21, 204-9	3.3	20
171	Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 2012-20	15.4	102
170	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. <i>Journal of Clinical Investigation</i> , 2015 , 125, 3766-81	15.9	34
169	Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis. <i>Blood</i> , 2015 , 126, 430-430	2.2	3
168	Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study. <i>Blood</i> , 2015 , 126, 759-759	2.2	

167	Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis. <i>Blood</i> , 2015 , 126, 1120-1120	2.2	
166	Outcomes of Low-Molecular-Weight Heparin treatment for Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors. <i>Blood</i> , 2015 , 126, 428-428	2.2	
165	Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. <i>Haemophilia</i> , 2014 , 20, 200-6	3.3	15
164	Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. <i>Haemophilia</i> , 2014 , 20, 527-34	3.3	37
163	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. <i>European Journal of Internal Medicine</i> , 2014 , 25, 847-52	3.9	1
162	Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. <i>The Cochrane Library</i> , 2014 , CD010561	5.2	4
161	Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2014 , 25, 617-23	3.9	62
160	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. <i>Nature</i> , 2014 , 511, 184-90	50.4	436
159	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 172-9	7	70
158	Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. <i>Haemophilia</i> , 2014 , 20, 777-83	3.3	13
157	Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. <i>American Journal of Public Health</i> , 2014 , 104, e12-22	5.1	187
156	Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients. <i>Haemophilia</i> , 2014 , 20, 800-6	3.3	12
155	Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update. <i>Revista Portuguesa De Pneumologia</i> , 2014 , 20, 324-35		11
154	Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. <i>Haemophilia</i> , 2014 , 20, e287-95	3.3	38
153	Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. <i>International Journal of Laboratory Hematology</i> , 2014 , 36, 341-51	2.5	28
152	Interventions for enhancing medication adherence. <i>The Cochrane Library</i> , 2014 , CD000011	5.2	629
151	Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. <i>Haemophilia</i> , 2014 , 20, 604-6	3.3	
150	First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. <i>Haemophilia</i> , 2014 , 20, e251-9	3.3	5

149	Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. <i>Haemophilia</i> , 2014 , 20, e199-204	3.3	9
148	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. <i>Internal and Emergency Medicine</i> , 2014 , 9, 723-34	3.7	95
147	Joint WFH-ISTH session: issues in clinical trial design. <i>Haemophilia</i> , 2014 , 20 Suppl 4, 137-44	3.3	6
146	Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. <i>Systematic Reviews</i> , 2014 , 3, 137	3	12
145	Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials. <i>Implementation Science</i> , 2014 , 9, 125	8.4	9
144	Epidemiology of Inhibitors in Hemophilia 2014 , 53-58		2
143	Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. <i>American Journal of Medicine</i> , 2014 , 127, 979-986.e2	2.4	26
142	Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. <i>Haemophilia</i> , 2014 , 20, 44-51	3.3	67
141	Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. <i>Blood</i> , 2014 , 124, 2818-2818	2.2	0
140	The haemophilia certification system in Canada. <i>Blood Transfusion</i> , 2014 , 12 Suppl 3, e531-41	3.6	3
139	A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia. <i>Blood</i> , 2014 , 124, 2821-2821	2.2	
138	Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013 , 15, 224-39	2.1	9
137	Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. <i>Drugs and Aging</i> , 2013 , 30, 103-12	4.7	120
136	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. <i>Internal and Emergency Medicine</i> , 2013 , 8, 509-20	3.7	17
135	High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 63	22.4	12
134	A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic reviews (ARROW): a study protocol. <i>Systematic Reviews</i> , 2013 , 2, 113	3	12
133	Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1655-62	15.4	47
132	Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale. <i>Pharmacoeconomics Italian Research Articles</i> , 2013 , 15, 45-63		2

131	Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013 , 24, 800-6	3.9	11
130	Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. <i>Journal of Clinical Epidemiology</i> , 2013 , 66, 415-25	5.7	7
129	Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study. <i>Internal and Emergency Medicine</i> , 2013 , 8, 55-63	3.7	
128	Risk factors for hospital readmission of elderly patients. <i>European Journal of Internal Medicine</i> , 2013 , 24, 45-51	3.9	58
127	Factor VIII products and inhibitors in severe hemophilia A. <i>New England Journal of Medicine</i> , 2013 , 368, 1457	59.2	9
126	Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study. <i>BioMed Research International</i> , 2013 , 2013, 901975	3	8
125	Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. <i>Gerontology</i> , 2013 , 59, 307-15	5.5	11
124	Adverse clinical events and mortality during hospitalization and 3 months after discharge in cognitively impaired elderly patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013 , 68, 419-25	6.4	22
123	The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. <i>Haemophilia</i> , 2013 , 19, 351-4	2.3	25
122	Drug-drug interactions in a cohort of hospitalized elderly patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1054-60	2.6	41
121	Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course—the Kogeniale project. <i>Blood Transfusion</i> , 2013 , 11, 272-80	3.6	1
120	Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1019-25	15.4	276
119	Clotting factor concentrate switching and inhibitor development in hemophilia A. <i>Blood</i> , 2012 , 120, 720-2	7.2	37
118	Prospettive di utilizzo della Valutazione Economica e della Budget Impact Analysis nelle politiche del farmaco in Italia: i risultati di uno studio Delphi. <i>Pharmacoeconomics Italian Research Articles</i> , 2012 , 14, 3-27		4
117	Uncertainties in baseline risk estimates and confidence in treatment effects. <i>BMJ, The</i> , 2012 , 345, e74015	5.9	37
116	Psychological interventions for people with hemophilia. <i>The Cochrane Library</i> , 2012 ,	5.2	3
115	Central nervous system bleeding in patients with rare bleeding disorders. <i>Haemophilia</i> , 2012 , 18, 34-8	3.3	25
114	Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. <i>Haemophilia</i> , 2012 , 18, 39-45	3.3	38

113	Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. <i>Haemophilia</i> , 2012 , 18, e101-14	3.3	78
112	Applicability of the AGREE II instrument in evaluating the development process and quality of current National Academy of Clinical Biochemistry guidelines. <i>Clinical Chemistry</i> , 2012 , 58, 1426-37	5.5	22
111	Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients. <i>International Psychogeriatrics</i> , 2012 , 24, 606-13	3.4	10
110	Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. <i>Blood</i> , 2012 , 120, 1186-1186	2.2	
109	Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life. <i>Blood</i> , 2012 , 120, 4244-4244		
108	Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. <i>European Journal of Internal Medicine</i> , 2011 , 22, 205-10	3.9	70
107	More about optimal choices in cardioembolism prevention. <i>European Journal of Internal Medicine</i> , 2011 , 22, e19	3.9	
106	Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2011 , 22, 597-602	3.9	83
105	ACP Journal Club. The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care. <i>Annals of Internal Medicine</i> , 2011 , 154, JC6-13	8	
104	Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. <i>Transfusion Medicine</i> , 2011 , 21, 280-4	1.3	6
103	Concentrate-related inhibitor risk: is a difference always real?. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 2176-9	15.4	25
102	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. <i>European Journal of Clinical Pharmacology</i> , 2011 , 67, 507-19	2.8	208
101	Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. <i>American Journal of Hematology</i> , 2011 , 86, 914-7	7.1	37
100	In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 930-6	3.9	26
99	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. <i>The Cochrane Library</i> , 2011 , CD003429	5.2	70
98	Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 802-9	5.3	44
97	Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 511-21	5.3	39
96	Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. <i>BMJ, The</i> , 2011 , 342, d813	5.9	165

95	Clinical efficacy and safety of moroctocog alfa. <i>Clinical Investigation</i> , 2011 , 1, 305-316		1
94	Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. <i>Blood</i> , 2011 , 118, 544-544	2.2	2
93	Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. <i>Blood Transfusion</i> , 2011 , 9, 60-9	3.6	11
92	Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study. <i>Blood</i> , 2011 , 118, 26-26	2.2	
91	Mortality and causes of death in Italian persons with haemophilia, 1990-2007. <i>Haemophilia</i> , 2010 , 16, 437-46	3.3	97
90	Bone mineral density in haemophilia patients. A meta-analysis. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 596-603	7	63
89	Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. <i>Cochrane Database of Systematic Reviews</i> , 2010 , CD004449		29
88	In-hospital death and adverse clinical events in elderly patients according to disease clustering: the REPOSI study. <i>Rejuvenation Research</i> , 2010 , 13, 469-77	2.6	35
87	Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. <i>Archives of Internal Medicine</i> , 2010 , 170, 1710-6		228
86	Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. <i>European Journal of Internal Medicine</i> , 2010 , 21, 516-23	3.9	44
85	Small intestinal bacterial overgrowth and warfarin dose requirement variability. <i>Thrombosis Research</i> , 2010 , 126, 12-7	8.2	19
84	Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. <i>Annals of Internal Medicine</i> , 2010 , 153, 523-31	8	120
83	Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. <i>Circulation</i> , 2010 , 121, 1838-47	16.7	307
82	Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. <i>The Cochrane Library</i> , 2010 , CD004888	5.2	12
81	Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3483-6	3.3	3
80	Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. <i>Archives of Internal Medicine</i> , 2010 , 170, 609-16		13
79	ACP Journal Club. A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. <i>Annals of Internal Medicine</i> , 2010 , 153, JC4-13	8	
78	Selective outcome reporting: telling and detecting true lies. The state of the science. <i>Internal and Emergency Medicine</i> , 2010 , 5, 151-5	3.7	16

77	Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2010 , 39, 356-65	2.3	45
76	Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1256-65	15.4	206
75	Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2313-5	15.4	77
74	Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 2436-42	15.4	142
73	A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. <i>Blood</i> , 2010 , 116, 710-710	2.2	
72	Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients. <i>Blood</i> , 2010 , 116, 238-238	2.2	
71	Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2335-41; quiz 2342	0.7	9
70	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. <i>American Journal of Hematology</i> , 2009 , 84, 584-8	7.1	51
69	Patients, physicians, and pharmacists preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. <i>Haemophilia</i> , 2009 , 15, 473-86	3.3	23
68	Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). <i>Haemophilia</i> , 2009 , 15, 779-87	3.3	19
67	Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?. <i>Haemophilia</i> , 2009 , 15, 900-3	3.3	12
66	Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009 , 124, e1-5	8.2	12
65	Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. <i>Blood</i> , 2009 , 114, 779-84	2.2	94
64	Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B. <i>Blood</i> , 2009 , 114, 4907-4908	2.2	5
63	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. <i>Blood</i> , 2009 , 114, 3993-3993	2.2	
62	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. <i>Blood</i> , 2009 , 114, 3154-3154	2.2	
61	Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.. <i>Blood</i> , 2009 , 114, 3494-3494	2.2	
60	Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. <i>Haemophilia</i> , 2008 , 14, 444-53	3.3	70

59	Iatrogenic causes of an ICH: OAT therapy. <i>European Journal of Anaesthesiology</i> , 2008 , 42, 8-11	2.3	
58	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. <i>Haematologica</i> , 2008 , 93, 722-8	6.6	73
57	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 52-8	7	38
56	Selecting references that match constructs: the difficult job of citing the parachute hyperbole. <i>Internal and Emergency Medicine</i> , 2008 , 3, 151-4	3.7	
55	Thrombophilia and cerebral vein thrombosis. <i>Frontiers of Neurology and Neuroscience</i> , 2008 , 23, 55-76	1.1	4
54	Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. <i>Blood Transfusion</i> , 2008 , 6, 211-9	3.6	11
53	The good use of plasma. A critical analysis of five international guidelines. <i>Blood Transfusion</i> , 2008 , 6, 18-24	3.6	24
52	Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. <i>Blood</i> , 2008 , 112, 3029-3029	2.2	
51	Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 635-641	7	11
50	Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence. <i>Internal and Emergency Medicine</i> , 2007 , 2, 202-6	3.7	2
49	Chronic prostatitis. <i>New England Journal of Medicine</i> , 2007 , 356, 423-4; author reply 424	59.2	1
48	Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 635-41	7	3
47	Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. <i>Cerebrovascular Diseases</i> , 2006 , 22, 286-93	3.2	33
46	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD003429		7
45	D-dimer testing to determine the duration of anticoagulation therapy. <i>New England Journal of Medicine</i> , 2006 , 355, 1780-9	59.2	493
44	Influenza vaccination in patients on long-term anticoagulant therapy. <i>Vaccine</i> , 2006 , 24, 6624-8	4.1	14
43	Can evidence harm? Certainly not hemophilia treatment and community. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 505-6	15.4	1
42	Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 2133-6	15.4	1

41	Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. <i>Haemophilia</i> , 2006 , 12, 128-32	3.3	26
40	Differences between patients, physicians and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. <i>Haemophilia</i> , 2005 , 11, 589-97	3.3	47
39	Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. <i>International Journal of Laboratory Hematology</i> , 2005 , 27, 283-5		12
38	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD003429		8
37	Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. <i>Current Pharmaceutical Design</i> , 2005 , 11, 3893-918	3.3	9
36	Performance Comparison of Three Assay Methods Used in Fasting and Postmethionine Load Plasma Homocysteine Determinations From Patients With Vascular Disease. <i>American Journal of Clinical Pathology</i> , 2005 , 124, 675-681	1.9	9
35	High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.. <i>Blood</i> , 2005 , 106, 3219-3219	2.2	
34	Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia.. <i>Blood</i> , 2005 , 106, 3114-3114	2.2	2
33	Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease. <i>American Journal of Clinical Pathology</i> , 2005 , 124, 675-81	1.9	4
32	Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1055-7	15.4	4
31	Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet disease and deep vein thrombosis. <i>Arthritis and Rheumatism</i> , 2004 , 51, 177-83		30
30	Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003 , 33, 197-201		24
29	Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 881-3	15.4	1
28	Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 1906-13	15.4	113
27	Influenza A virus specific T cell immunity in humans during aging. <i>Virology</i> , 2002 , 299, 100-8	3.6	56
26	Successful treatment of Dieulafoy disease in a von Willebrand patient. <i>Haematologica</i> , 2002 , 87, ECR236.6	3.6	1
25	Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. <i>Haematologica</i> , 2002 , 87, 948-56	6.6	13
24	Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. <i>New England Journal of Medicine</i> , 2001 , 345, 165-9	59.2	467

23	Serine base exchange enzyme in porcine lyophilised platelets: enzyme properties and modulation by ALF4- and different types of heparin. <i>Molecular and Cellular Biochemistry</i> , 2000 , 203, 177-84	4.2	2
22	Mesenteric-portal Vein Thrombosis in a Patient with Hyperhomocysteinemia and Heterozygous for 20210A Prothrombin Allele. <i>Thrombosis and Haemostasis</i> , 2000 , 84, 358-359	7	6
21	Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 794-795	7	22
20	Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. <i>Archives of Internal Medicine</i> , 2000 , 160, 2327-32		173
19	Miconazole oral gel potentiates warfarin anticoagulant activity. <i>Thrombosis and Haemostasis</i> , 2000 , 83, 794-5	7	7
18	Mesenteric-portal vein thrombosis in a patient with hyperhomocysteinemia and heterozygous for 20210A prothrombin allele. <i>Thrombosis and Haemostasis</i> , 2000 , 84, 358-9	7	2
17	Withdrawal of warfarin after deep vein thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 1999 , 10, 291-296		13
16	Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. <i>New England Journal of Medicine</i> , 1998 , 339, 80-5	59.2	432
15	Choice of End-points in Assessing the Efficacy of Post-discharge Prophylaxis for Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 234-234	7	3
14	Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. <i>Blood Coagulation and Fibrinolysis</i> , 1997 , 8, 216-22	1	15
13	Pharmacokinetic optimisation of the treatment of deep vein thrombosis. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 145-72	6.2	10
12	Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1997 , 27, 85-90		1
11	Different mechanisms regulate phosphatidylserine synthesis in rat cerebral cortex. <i>Molecular and Cellular Biochemistry</i> , 1997 , 168, 41-9	4.2	10
10	Post-discharge deep-vein thrombosis after orthopaedic surgery. <i>Lancet, The</i> , 1996 , 348, 1180	40	1
9	Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 395-400	7	18
8	Non-Anticoagulant Actions of Glycosaminoglycans 1996 , 101-112		
7	Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. <i>Thrombosis and Haemostasis</i> , 1996 , 75, 395-400	7	2
6	Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. <i>Circulation</i> , 1995 , 92, 2819-24	16.7	27

5	Antipyretic analgesics. <i>Side Effects of Drugs Annual</i> , 1994 , 18, 90-98	0.2	
4	Plasma thrombin neutralization assay: pharmacokinetic applications. <i>Seminars in Thrombosis and Hemostasis</i> , 1994 , 20, 266-73	53	3
3	Dermatan sulphate in heparin-induced thrombocytopenia. <i>Lancet, The</i> , 1994 , 344, 1295-6	40	22
2	Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet-rich plasma. <i>Fibrinolysis</i> , 1993 , 7, 379-385		5
1	A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study (Preprint)		2